Major need for safer antiarrhythmic drugs will continue to plague atrial fibrillation market

Despite the restoration and maintenance of sinus rhythm being a common practice in the management of atrial fibrillation, the available antiarrhythmic drugs are of modest efficacy and have unfavorable safety profiles.
Although the overall level of unmet need in the atrial fibrillation market is generally considered moderate, the need for safer antiarrhythmic drugs for the maintenance of sinus rhythm is still a major issue in the treatment space, according to research and consulting firm GlobalData.
The company’s report states that despite the restoration and maintenance of sinus rhythm being a common practice in the management of atrial fibrillation, the available antiarrhythmic drugs are of modest efficacy and have unfavorable safety profiles. For example, amiodarone is a widely used generic antiarrhythmic drug, and despite being considered an effective agent available for heart rhythm control, it has a number of side effects including proarrhythmia, and thyroid, liver, skin, and pulmonary complications.
Jesus Cuaron, GlobaData’s Senior Analyst covering Cardiovascular and Metabolic Disorders, explains: “Antiarrhythmic drug development has been very slow and there are presently no late-stage drug candidates that are expected to address this unmet need by 2025. In addition, most antiarrhythmic drugs are already genericized and more will follow, contributing to a rapid decline in market value from 2022.”
Two of the more promising antiarrhythmic drugs that had just entered, or were expected to enter, Phase III clinical trials, recently had their development discontinued, namely Gilead’s fixed-dose combination of ranolazine/dronedarone and Laguna Pharmaceuticals’ vanoxerine. In the early-stage antiarrhythmic drug pipeline, there are only three drug candidates in Phase II and one drug in Phase I development for atrial fibrillation.
Cuaron explains: “Part of the reason for the low level of activity in the pipeline is due to the high risk involved in developing an antiarrhythmic drug. Large and costly clinical trials are required to demonstrate that a drug is safe and effective, and the track record for those antiarrhythmic drugs that have reached the market in the past decade has been disappointing.
“It is also expected that the availability of cheaper generic alternatives and the continuing cost constraints faced by national health authorities will make it difficult for drugs to obtain reimbursement and subsequent addition to hospital formularies. With continued advances in technology, it is expected that there will be a move towards using procedural technologies, such as catheter ablation, as the preferred treatment option for rhythm control.”
Related News
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease. -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance